Meeting: 2014 AACR Annual Meeting
Title: Mechanism-based combinatorial treatment of KRAS mutant colorectal
cancer with MEK and PI3K pathway inhibitors


Treatment of metastatic colorectal cancer remains a considerable hurdle
as typically 2) agents or intermittent/alternating treatment strategies
will be required.

